KPTI News and Press, Karyopharm Therapeutics Inc. From 02/08/22

Karyopharm Therapeutics Inc. (KPTI) Q4 2021 Earnings Conference Call February 8, 2022 8:30 am ET Company Participants Richard Paulson - President, Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Jatin Shah - Chief Medical Officer Michael Mason - Chief Financial Officer Sarah ...

Shares of Karyopharm Therapeutics (NASDAQ: KPTI) , a biopharmaceutical company, are sputtering today in response to lackluster clinical trial results for the company's lead drug. Investors worried about Xpovio's ability to reach a new patient population pushed the stock 21.8% lower ...

Gainers: Society Pass (NASDAQ:SOPA) +57%. Tritium DCFC Limited (NASDAQ:DCFC) +36%. Peloton Interactive (NASDAQ:PTON) +29%. IN8bio (NASDAQ:INAB) +22%. Teradata Corporation (NYSE:TDC) +24%. Atomera (NASDAQ:ATOM) +21%. BioCardia (NASDAQ:BCDA) +20%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +18%. ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q4 - Results - Earnings Call Presentation

Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...

Although it met its primary endpoint, the results of a late-stage trial of Karyopharm's (NASDAQ:KPTI) Xpovio (selinexor) in endometrial cancer are being viewed as a disappointment. Shares are down 13% in premarket trading. The phase 3 trial is designed to support a supplemental new ...

SelectQuote (NYSE:SLQT) -51% on Q2 earnings release Editas Medicine (NASDAQ:EDIT) -14% following chief medical officer termination. Micro Focus International (NYSE:MFGP) -13% on FY earnings release. Karyopharm Therapeutics (NASDAQ:KPTI) -11% on Q4 earni...

Karyopharm Therapeutics press release (NASDAQ:KPTI): Q4 EPS of $0.46 may not be comparable to consensus of -$0.42. Revenue of $126.2M (+259.5% Y/Y) beats by $94.28M. Based on its current operating plans, Karyopharm expects the following for full year 2022: XPOVIO net product revenue to be in ...

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress -- XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to $...

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer - Selinexor Demonstrates Statistically Significant 50% Improvement in Median Progressio...